Identification of a pyroptosis-related lncRNA signature as a novel prognostic biomarker for hepatocellular carcinoma

doi:10.3877/cma.j.issn.1674-0793.2023.05.008

Abstract

Abstract:

Objective

To clarify the expression of pyroptosis-related lncRNAs in hepatocellular carcinoma (HCC) and their relevance to prognosis by constructing a model of pyroptosis-related lncRNAs and validating their functions in an independent cohort of patients with HCC.

Methods

A pyroptosis-related multi-lncRNA signature was constructed using a cancer genome atlas (TCGA) cohort to predict the HCC patient prognosis. The least absolute shrinkage and selection operator (LASSO) Cox regression method were used to estalish four lncRNA models and classify all HCC patients into high-risk group or low-risk group.

Results

The patients in the low-risk group had a better prognosis than the high-risk group, and the risk score was an independent predictor for HCC patients. The sensitivity of drugs such as gemcitabine, doxorubicin, mitomycin C and sorafenib, the expression of immune cells such as mast resting cells, monocytes, NK resting cells, CD8⁺ T cells, and M0 macrophages showed significantly different infiltration degree between the two groups (P<0.05). Enrichment analysis for the differential genes in the two groups of patients was performed. Intriguingly, the result showed that targeting the Wnt/β-catenin signal pathway could help to develop treatment strategies for patients with HCC.

Conclusions

This study has discovered a signature of pyroptosis-related lncRNA, which can be used as an independent prognostic indicator for HCC patients, providing new insights for reliably and accurately predicting prognosis and developing therapeutic strategies for HCC patients.

Key words: Hepatocellular carcinoma, Prognosis, Pyroptosis, lncRNA, TCGA

Wei Huang, Qi Liu, Liuhua Chen, Chaxiang Teng, Zhejian Ou, Hanxiao Liu, Jiancong Chen, Kunsong Zhang. Identification of a pyroptosis-related lncRNA signature as a novel prognostic biomarker for hepatocellular carcinoma[J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(05): 357-365.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2023.05.008

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2023/V17/I05/357

Figures/Tables 10

References 24

[1]	Liu PH, Hsu CY, Hsia CY, et al. Prognosis of hepatocellular carcinoma: assessment of eleven staging systems[J]. J Hepatol, 2016, 64(3): 601-608.
[2]	Fang Y, Tian S, Pan Y, et al. Pyroptosis: A new frontier in cancer[J]. Biomed Pharmacother, 2020, 121: 109595.
[3]	Hage C, Hoves S, Strauss L, et al. Sorafenib induces pyroptosis in macrophages and triggers natural killer cell-mediated cytotoxicity against hepatocellular carcinoma[J]. Hepatology, 2019, 70(4): 1280-1297.
[4]	Huang Z, Zhou JK, Peng Y, et al. The role of long noncoding RNAs in hepatocellular carcinoma[J]. Mol Cancer, 2020, 19(1): 77.
[5]	Chen Z, He M, Chen J, et al. Long non-coding RNA SNHG7 inhibits NLRP3-dependent pyroptosis by targeting the miR-34a/SIRT1 axis in liver cancer[J]. Oncol Lett, 2020, 20(1): 893-901.
[6]	Karki R, Kanneganti TD. Diverging inflammasome signals in tumorigenesis and potential targeting[J]. Nat Rev Cancer, 2019, 19(4): 197-214.
[7]	Man SM, Kanneganti TD. Regulation of inflammasome activation[J]. Immunol Rev, 2015, 265(1): 6-21.
[8]	Wang B, Yin Q. AIM2 inflammasome activation and regulation: A structural perspective[J]. J Struct Biol, 2017, 200(3): 279-282.
[9]	Xia X, Wang X, Cheng Z, et al. The role of pyroptosis in cancer: pro-cancer or pro- "host" ?[J]. Cell Death Dis, 2019, 10(9): 650.
[10]	Colaprico A, Silva TC, Olsen C, et al. TCGAbiolinks: An R/bioconductor package for integrative analysis of TCGA data[J]. Nucleic Acids Res, 2016, 44(8): e71.
[11]	Shen Z, Zhou H, Li A, et al. Metformin inhibits hepatocellular carcinoma development by inducing apoptosis and pyroptosis through regulating FOXO3[J]. Aging (Albany NY), 2021, 13(18): 22120-22133.
[12]	Zhu Q, Yang H, Cheng P, et al. Bioinformatic analysis of the prognostic value of the lncRNAs encoding snoRNAs in hepatocellular carcinoma[J]. Biofactors, 2019, 45(2): 244-252.
[13]	Jiao Y, Li Y, Jia B, et al. The prognostic value of lncRNA SNHG4 and its potential mechanism in liver cancer[J]. Biosci Rep, 2020, 40(1): BSR20190729.
[14]	Patrikidou A, Sinapi I, Regnault H, et al. Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies[J]. Invest New Drugs, 2014, 32(5): 1028-1035.
[15]	Zaanan A, Williet N, Hebbar M, et al. Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: A large multicenter AGEO study[J]. J Hepatol, 2013, 58(1): 81-88.
[16]	Elsadek B, Mansour A, Saleem T, et al. The antitumor activity of a lactosaminated albumin conjugate of doxorubicin in a chemically induced hepatocellular carcinoma rat model compared to sorafenib[J]. Dig Liver Dis, 2017, 49(2): 213-222.
[17]	Liu N, Tan Y, Hu Y, et al. A54 peptide modified and redox-responsive glucolipid conjugate micelles for intracellular delivery of doxorubicin in hepatocarcinoma therapy[J]. ACS Appl Mater Interfaces, 2016, 8(48): 33148-33156.
[18]	Gruber-Rouh T, Kamal A, Eichler K, et al. Transarterial chemoembolization (TACE) using mitomycin with or without irinotecan for hepatocellular carcinoma in european patients[J]. Oncol Res Treat, 2018, 41(7-8): 438-442.
[19]	Zucman-Rossi J, Villanueva A, Nault JC, et al. Genetic landscape and biomarkers of hepatocellular carcinoma[J]. Gastroenterology, 2015, 149(5): 1226-1239, e4.
[20]	Eggert T, Wolter K, Ji J, et al. Distinct functions of senescence-associated immune responses in liver tumor surveillance and tumor progression[J]. Cancer Cell, 2016, 30(4): 533-547.
[21]	Kang TW, Yevsa T, Woller N, et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development[J]. Nature, 2011, 479(7374): 547-551.
[22]	He S, Tang S. WNT/β-catenin signaling in the development of liver cancers[J]. Biomed Pharmacother, 2020, 132: 110851.
[23]	Toh TB, Lim JJ, Hooi L, et al. Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma[J]. J Hepatol, 2020, 72(1): 104-118.
[24]	Huynh H, Ong R, Goh KY, et al. Sorafenib/MEK inhibitor combination inhibits tumor growth and the Wnt/β-catenin pathway in xenograft models of hepatocellular carcinoma[J]. Int J Oncol, 2019, 54(3): 1123-1133.

项目	训练集	验证集	χ²值	P值
例数	177	166
年龄(岁)			0.381	0.537
>60	89(50.3)	89(53.6)
≤60	88(49.7)	77(46.4)
性别			44.278	<0.001
男	59(33.3)	115(69.3)
女	118(66.7)	51(30.7)
AJCC M分期			2.636	0.268
M0	133(75.1)	112(67.5)
M1	1(0.6)	2(1.2)
NA	43(24.3)	52(31.3)
AJCC N分期			4.078	0.130
N0	127(71.7)	112(67.5)
N1	3(1.7)	0(0)
NA	47(26.6)	54(32.5)
AJCC分级			3.501	0.478
G1	22(12.5)	31(18.7)
G2	85(48.0)	76(45.8)
G3	62(35.0)	50(30.1)
G4	5(2.8)	7(4.2)
NA	3(1.7)	2(1.2)
AJCC分期			0.833	0.934
1	85(48.0)	76(45.8)
2	40(22.6)	37(22.3)
3	41(23.2)	39(23.5)
4	1(0.6)	2(1.2)
NA	10(5.6)	12(7.2)
AJCC T分期			0.500	0.974
T1	88(49.7)	80(48.2)
T2	43(24.3)	41(24.7)
T3	38(21.5)	37(22.3)
T4	6(3.4)	7(4.2)
NA	2(1.1)	1(0.6)

项目	训练集	验证集	χ²值	P值
例数	177	166
年龄(岁)			0.381	0.537
>60	89(50.3)	89(53.6)
≤60	88(49.7)	77(46.4)
性别			44.278	<0.001
男	59(33.3)	115(69.3)
女	118(66.7)	51(30.7)
AJCC M分期			2.636	0.268
M0	133(75.1)	112(67.5)
M1	1(0.6)	2(1.2)
NA	43(24.3)	52(31.3)
AJCC N分期			4.078	0.130
N0	127(71.7)	112(67.5)
N1	3(1.7)	0(0)
NA	47(26.6)	54(32.5)
AJCC分级			3.501	0.478
G1	22(12.5)	31(18.7)
G2	85(48.0)	76(45.8)
G3	62(35.0)	50(30.1)
G4	5(2.8)	7(4.2)
NA	3(1.7)	2(1.2)
AJCC分期			0.833	0.934
1	85(48.0)	76(45.8)
2	40(22.6)	37(22.3)
3	41(23.2)	39(23.5)
4	1(0.6)	2(1.2)
NA	10(5.6)	12(7.2)
AJCC T分期			0.500	0.974
T1	88(49.7)	80(48.2)
T2	43(24.3)	41(24.7)
T3	38(21.5)	37(22.3)
T4	6(3.4)	7(4.2)
NA	2(1.1)	1(0.6)

Please choose a citation manager

Content to export